Worcester Chamber Exchange - August 2020
Galaxy’s purchase is the second transaction at the 46-acre, master-planned park in the last few months, following China-based WuXi Biologics’ purchase to build their first U.S. production facility by 2022. Read More
Worcester Telegram & Gazette – August 2020
Galaxy Life Sciences LLC, whose sister company developed the Trolley Yard, has inked a deal to build an estimated $50 million building on a 6-acre plot at The Reactory biomanufacturing park. The deal also grants Galaxy Life Sciences the right to develop the remainder of the available lots in the biomanufacturing park on the former Worcester State Hospital campus. Read More
Worcester Business Journal – August 2020
"The need for flexible and sustainable biomanufacturing in the region has never been greater,” said Mike O’Brien, CEO of Galaxy Life Sciences. “We stand ready and able to help our potential life sciences partners turn their innovative ideas into commercial products at faster-than-industry-average speed to market". Read More
June 16, 2020
A virtual ceremony on Zoom was held today to celebrate both the completion of the recent land agreement between WuXi Biologics (WuXi Bio) and the Worcester Business Development Corporation (WBDC), and the start of construction of the WuXi Bio MFG11 biopharmaceutical manufacturing facility at The Reactory in Worcester, Mass.
New England Real Estate Journal – June 2020
Worcester, MA WuXi Biologics (WuXi Bio), and Worcester Business Development Corp. (WBDC) have signed a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) at The Reactory, a 46-acre master-planned biomanufacturing campus. WuXi Biologics, a global company with leading open-access biologics technology platforms, empowers biopharma organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The $60 million, 107,000 s/f, two-story facility will be operational in 2022 and create 150 new jobs. Read More
Forbes - June 2020
“As the central Massachusetts biotech community continues its growth, WuXi Biologics’ arrival in Worcester will strengthen the sector and lead to ongoing economic development,” said Massachusetts Lt. Governor Karyn Polito. “Years of planning and collaboration to transform an unused property into a biomanufacturing hub has led to this exciting announcement today and I appreciate the commitment of so many to making this a reality.” Read More
BioProcess International - May 2020
Along with several additional single-use biomanufacturing plants in China, WuXi Biologics set its sites on global expansion, first announcing plans for a 54,000 L plant in Ireland, then a 4,500 L fed-batch and perfusion-based facility in Singapore, and finally a site in in Worcester, Massachusetts, US. Read More
FiercePharma - May 2020
WuXi Biologics has angled for years to expand its manufacturing base out of China and into promising hubs in Europe and the U.S. Now, nearly two years after its plans were first announced, WuXi has secured a deal to build a new facility in Massachusetts in the biotech hotbed of the greater Boston area. Read More
CNBC - May 2020
The White House is preparing an executive order which will require certain essential drugs be made in the U.S., two sources familiar with the matter told CNBC. Read More
Worcester Telegram - March 2020
The City Council Economic Development Committee Monday night unanimously endorsed a 20-year tax increment financing plan for the project that would save the company roughly $11.5 million in property taxes over the life of the plan. During that period, the city would receive $20.7 million in new tax revenue from the project. Read More